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A B S T R A C T
Purpose
To determine whether overall survival (OS) can be preserved for patients with stage I pediatric
malignant ovarian germ cell tumor (MOGCT) with an initial strategy of surveillance after
surgical resection.
Patients and Methods
Between November 2003 and July 2011, girls age 0 to 16 years with stage I MOGCT were
enrolled onto Children’s Oncology Group study AGCT0132. Required histology included yolk sac,
embryonal carcinoma, or choriocarcinoma. Surveillance included measurement of serum tumor
markers and radiologic imaging at defined intervals. In those with residual or recurrent disease,
chemotherapy with compressed PEB (cisplatin, etoposide, and bleomycin) was initiated every 3
weeks for three cycles (cisplatin 33 mg/m2 on days 1 to 3, etoposide 167 mg/m2 on days 1 to 3,
bleomycin 15 U/m2 on day 1). Survivor functions for event-free survival (EFS) and OS were
estimated using the Kaplan-Meier method.
Results
Twenty-five girls (median age, 12 years) with stage I MOGCT were enrolled onto AGCT0132.
Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis. Predominant histology
was yolk sac. After a median follow-up of 42 months, 12 patients had evidence of persistent or
recurrent disease (4-year EFS, 52%; 95% CI, 31% to 69%). Median time to recurrence was 2
months. All patients had elevated AFP at recurrence; six had localized disease, two had metastatic
disease, and four had tumor marker elevation only. Eleven of 12 patients experiencing relapse
received successful salvage chemotherapy (4-year OS, 96%; 95% CI, 74% to 99%).
Conclusion
Fifty percent of patients with stage I pediatric MOGCT can be spared chemotherapy; treatment for
those who experience recurrence preserves OS. Further study is needed to identify the factors
that predict recurrence and whether this strategy can be extended successfully to older
adolescents and young adults.
J Clin Oncol 32:465-470. © 2014 by American Society of Clinical Oncology
INTRODUCTION
In the prechemotherapy era, even localized malig-
nant nongerminomatous ovarian germ cell tumors
were associated with survival of only 20%.1 The ad-
vent of platinum-based chemotherapy for testicular
cancer in 1977 dramatically improved survival2 and
was subsequently applied to all extracranial sites in
children.3 Although survival for those with early-
stage pediatric malignant germ cell tumors treated
with platinum-based chemotherapy is currently 
90%,3,4 life-threatening late effects of chemotherapy
remain a challenge. Renal impairment, neurotoxic-
ity, and hearing loss are well-recognized toxicities in
pediatric patients treated for germ cell tumors.5 Re-
cent long-term follow-up studies of men with testic-
ular cancer have demonstrated that the risk of
cardiovascular disease and second malignancy is in-
creased two-fold6; similar long-term studies of late
effects do not yet exist for children, although the
treatment regimens for adult and pediatric germ cell
tumors are nearly identical. Among men who were
treated for testicular cancer with cisplatin-based
chemotherapy at age 20 years, the rate of second
malignant neoplasm (SMN) was 50% by age 75
years, analogous or even higher than the rate of SMN
seen in patients with Hodgkin lymphoma.6 Because
as many as 75% of men with stage I testicular cancer
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are cured with surgery alone, and salvage with chemotherapy is suc-
cessful in those who experience recurrence, surveillance is now an
accepted standard of care in men with stage I testicular cancer.7 These
findings, and the recent success of a surgery-only watch-and-wait
strategy for stage I testis tumors in prepubertal boys,8 motivated the
design of our study to assess whether a surveillance strategy with
strictly defined surgical guidelines could be extended to stage I malig-
nant ovarian germ cell tumors (MOGCTs) in pediatric and adoles-
cent girls.
PATIENTS AND METHODS
Patients
On the basis of the results of the last intergroup pediatric germ cell trial,
INT-0016,3 the Children’s Oncology Group (COG) protocol AGCT0132 di-
vided pediatric germ cell tumors into three categories: low, intermediate, and
high risk (Fig 1). Low-risk patients had stage I ovarian and testicular germ cell
tumors; AGCT0132 prescribed a surveillance strategy for low-risk gonadal
tumors. Intermediate-risk patients were defined as having stage I to II extrago-
nadal, stage III ovarian, or stage III to IV testicular tumors; these patients
received three cycles of compressed pediatric BEP (bleomycin, etoposide, and
platinum; PEB [cisplatin, etoposide, and bleomycin]). PEB differs from adult
BEP; bleomycin is administered once per cycle with PEB versus once per week
with BEP. High-risk patients, defined as having stage III to IV extragonadal
tumors, were excluded from this trial. Patients were required to have one of the
following histologic elements: yolk sac, choriocarcinoma, or embryonal carci-
noma; pure seminoma/dysgerminoma and immature teratoma and/or malig-
nant somatic transformation were excluded. Institutional review board
approval was obtained at participating centers.
Required data for enrollment onto the low-risk stratum of AGCT0132
included adherence to surgical guidelines (Table 1), submission of operative
note and surgical checklist, metastatic imaging at diagnosis, and central pa-
thology review. Patients were to be enrolled within 6 weeks of initial diagnosis.
Patients could be enrolled onto the low-risk stratum if their tumor markers
were elevated but not rising. If tumor markers failed to decline according to a
7-day half-life up 6 weeks after diagnosis, or if central review of submitted
materials indicated the patient did not have stage I disease, the institutional
investigator was to start administering therapy, and the patient was not con-
sidered in the analysis of the low-risk strategy.
Treatment
The surveillance strategy for patients with stage I disease managed with
surgery only required measurement of serum markers alpha-fetoprotein
(AFP) and beta human chorionic gonadotrophin (-HCG) every 3 weeks
through week 9, every month from months 2 to 6, and every 3 months from
months 6 to 24. Patients in the surveillance stratum whose serum tumor
markers failed to decrease at the expected rate after initial surgery or had
radiologic evidence of relapse were transferred to the intermediate-risk stra-
tum. Chemotherapy for intermediate-risk patients consisted of three cycles of
Enrolled
(n = 302)
Eligible
(n = 286)
Ineligible
(n = 16)
Low-risk patients
(n = 105)
Tumor recurrence on observation
(n = 31)
Intermediate-risk patients
(n = 181)
New intermediate-risk
patients 
(n = 211)
Ovarian tumors
(n = 25)
No events
(n = 61)
Events
(n = 19)
No treatment
(n = 1)
Received standard
AGCT0132 treatment
(n = 30)
No events
(n = 13)
Events
(n = 12)
Testicular tumors
(n = 80)
Fig 1. Patient flow diagram: low- and
intermediate-risk patients.
Table 1. COG Surgical Guidelines for Ovarian MGCT
Guideline
Collection of peritoneal fluid or washings for cytology
Examination of peritoneal surfaces with biopsy of any abnormal areas
Palpate retroperitoneal lymph nodes; biopsy only if abnormal (firm or
enlarged)
Inspect omentum; biopsy only if abnormal
Palpate/inspect opposite ovary; biopsy only if abnormal
Complete resection of involved ovary intact (no capsule entry on field) with
sparing of fallopian tube if not involved
Abbreviations: COG, Children’s Oncology Group; MGCT, malignant germ
cell tumor.
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compressed PEB. The compressed regimen included: cisplatin 33.3 mg/m2 on
days 1 to 3, etoposide 167 mg/m2 on days 1 to 3, and bleomycin 15 U/m2 on
day 1.
Data monitoring during the study revealed a higher-than-expected event
rate in the low-risk stratum, and enrollment was temporarily suspended. The
initial statistical design had employed a model predicting that failures would
occur at a uniform rate for the first 3 years after enrollment. Data from the
previous study, INT-106, became available after AGCT0132 was opened and
demonstrated that 80% of failures occurred within the first year after enroll-
ment. The low-risk arm was reopened with a revised statistical modeling of
predicted time to failure. Rapid review of eligibility data was conducted by a
COG study surgeon within 72 hours of enrollment, including review of the
operative note, pathology report, surgical checklist, and imaging findings.
Reassignment to a higher stage based on this rapid review was at the discretion
of the enrolling institution.
Statistical Analysis
Event-free survival (EFS) was measured from time of enrollment to
disease progression, diagnosis of an SMN, death, or last patient contact, which-
ever occurred first. Patients who did not experience an EFS event were cen-
sored at last contact. Overall survival (OS) was measured from time of
enrollment to death or last patient contact, whichever occurred first. Patients
who did not experience an OS event were censored at last contact. Survivor
functions for EFS and OS were estimated using the Kaplan-Meier method.9
CIs for the survivor functions were calculated using complementary log-
log transformation.9
The AGCT0132 low-risk stratum was designed to enroll 126 patients
with stage I testicular or ovarian cancer over 6 years, with 1 year of follow-up
after the last enrollment. The estimated survival curve was to be compared
with a piecewise exponential failure model with 5-year survival of 95% using
the Woolson one-sample log-rank test.10 A one-sided test of .10 indicated a
significant departure from survival model. The design had 80% power to
detect a decrease in 5-year survival to 83%. Interim monitoring of risk of death
was performed using the method of Lan and DeMets11 annually, with a
spending function that was linear in information time. In addition, interim
monitoring of the risk of EFS was conducted. At the time of primary survival
analysis, the estimated EFS curve was to be compared with a piecewise expo-
nential failure model with 5-year EFS of 70% using the Woolson one-sample
log-rank test.10 A one-sided test of .10 indicated a significant departure from
the EFS model. An EFS of 70% was chosen because this was greater than that
observed for men with low-risk testicular cancer, and there was uncertainty
regarding whether pediatric patients experiencing disease progression could as
readily successfully respond to salvage chemotherapy as adult patients. Interim
monitoring of risk of EFS event was performed annually using the method of
Lan and DeMets,11 with a spending function that was linear in information
time. If the interim monitoring rule indicated either excessive risk of death or
EFS event, the trial was referred to the COG Data Safety Monitoring Commit-
tee for possible termination of enrollment.
Prognostic variables considered in the analysis included serum AFP
obtained before tumor surgery ( 10,000 v 10,000 IU/L), age at diagnosis
( 10 v  11 years), maximum tumor dimension ( 20 v  21 cm), and
histology (pure yolk sac tumor [YST] v all others). Possible association be-
tween risk for EFS event and prognostic factor was assessed using the log-rank
test. Characteristics associated with P values  .05 were considered signifi-
cantly associated with risk of EFS event.
RESULTS
AGCT0132 was opened in November 2003 (Fig 1). Enrollment of
patients onto the low-risk stratum was stopped in January 2010 be-
cause there was significant evidence that 3-year EFS was  70%. A
total of 105 eligible patients were enrolled onto the low-risk stratum of
AGCT0132, including 80 male patients with stage I testis tumors and
25 female patients with stage I ovarian tumors. Results of the male
patients in the low-risk stratum and of the patients in the
intermediate-risk stratum will be reported elsewhere. The 25 female
patients with stage I ovarian tumors undergoing follow-up with sur-
gery and surveillance form the basis for this report.
The surgical reviewer’s assessment of stage was concordant with
the institutional assessment of stage in 21 patients and was discordant
Table 2. Patient Demographic and Clinical Characteristics
Characteristic No. %
Age at enrollment, years
 10 8 32.0
 11 17 68.0
Median 12
Range 0-16
Race
White 16 64.0
Black 5 20.0
Asian 2 8.0
Unknown 2 8.0
Tumor marker (AFP)
AFP elevated at diagnosis 23
Median AFP level at diagnosis 3,715
Range 19-2,220,000
AFP ever normalized
No 9 39.1
Yes 14 60.9
Time to normalization, days
Median 22.5
Range 12-153
Histology
Pure YST 8 32.0
YST plus MT only 3 12.0
YST plus IT 7 28.0
Mixed malignant† 7 28.0
YST at diagnosis, %
 1 2 8.0
1-4 6 24.0
5-49 4 16.0
50-99 4 16.0
100 8 32.0
Unknown 1 4.0
Median 37.5
Range 0.5-100
Tumor size, cm
1-10 1 4.0
11-20 14 56.0
21-30 6 24.0
31-35 1 4.0
Unknown 3 12.0
Median 18.8
Range 10-33
Stage review
Concordant 21 84.0
Discordant 4 16.0
Relapse
No. of patients 12 48.0
Median time to relapse, days 64.5
Range 31-237
Abbreviations: AFP, alpha-fetoprotein; IT, immature teratoma; MT, mature
teratoma; YST, yolk sac tumor.
IT had to be grade 2 or 3; patients who had YST, IT, and MT were also
included in this group.
†Includes one patient who was not classified.
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in four patients; the enrolling institution in all four cases elected to
have patients continue in the low-risk stratum despite the results of the
eligibility review. The reasons for the discordance between the enroll-
ing institution and study physician review resulted from the findings
of tumor rupture documented in the operative notes and/or pathol-
ogy reports in three patients and the failure to collect peritoneal cytol-
ogy in the remaining patient.
Two thirds of patients were age 10 years at diagnosis; the oldest
patientenrolledontothetrialwasage16years(Table2).AFPwaselevated
in all but two patients at diagnosis. At central pathologic review, presence
ofamalignantcomponentwasconfirmedin24of25patients.Inonecase,
the central reviewer did not agree that there was a microscopic focus of
YST within the immature teratoma, but the patient was not removed
from the protocol by the treating institution, as was its purview. YST was
the primary malignant histology; eight patients had pure YST, three had
YST mixed with mature teratoma, and seven had YST mixed with imma-
tureteratoma.Tumorsizewasavailable in22patientsandrangedfrom10
to 33 cm (median, 18.8 cm).
EFS at 4 years after enrollment was 52% (95% CI, 31% to 69%),
and OS was 96% (95% CI, 74% to 99%; Fig 2). Tumor events requir-
ing initiation of salvage chemotherapy occurred in 12 low-risk patients
from 1 to 8 months after initial surgery (median, 2 months; Table 3).
All patients experiencing recurrence had an increase in their AFP level.
In four patients, despite the rise in AFP, no mass could be detected by
imaging. Among the remaining eight patients, five had disease local-
ized to the pelvis, two had metastatic disease (liver and pleura), and
one had a site of relapse not specified by the institution. All patients
responded to three cycles of PEB chemotherapy. Two patients had a
second relapse after initial PEB therapy. The first patient had a second
relapse within 6 weeks of completing the initial three cycles of PEB and
was treated with alternate chemotherapy with intermittent normaliza-
tion of markers but new appearance of progressive disease by imaging
in multiple places within the abdominal cavity. Biopsy was performed
after completion of her second regimen of chemotherapy and showed
viable YST. She died as a result of tumor progression at 16 months
after initial diagnosis. The second patient was treated with taxol, ifos-
famide, and carboplatin after enrollment onto COG study AGCT0521
and remained alive and disease free 2 years after completing sal-
vage therapy.
Risk of relapse was not significantly related to age, preoperative
AFP, histology, or tumor size (data not shown). In 18 girls with
concordant pathology and intact tumor capsule, additional detailed
pathology comment was available. Events were seen in six of 15 girls
whose primary tumor had an uninvolved capsule compared with two
of three girls with evidence of capsule penetration (partial invasion of
intact capsule wall).
DISCUSSION
In this study of 25 girls with stage I tumors treated initially with close
surveillance, 12 girls experienced either failure of tumor marker de-
cline or evidence of relapse and required initiation of chemotherapy;
11 of 12 received successful salvage chemotherapy (4-year EFS, 52%;
95% CI, 31% to 69%; 4-year OS, 96%; 95% CI, 74% to 99%). All
events occurred within the first 8 months after surgery, with a median
of 60 days, and all recurrences were accompanied by rising AFP. The
prognostic significance of AFP, tumor size, age, and histology was null;
however, the evaluation of prognostic factors was limited by the small
number of individuals and EFS events observed in this cohort.
The so-called hidden site in the abdominal cavity allows ovarian
germ cell tumors to reach a greater size before detection than their
testicular counterpart. The risk of tumor rupture before or at time of
surgery is significant, with the potential for contamination of a large
cavity. Because the risk of malignancy for ovarian neoplasms in child-
hood and adolescence is only 10% to 20%,12 a surgeon may fail to
consider the possibility of malignancy at the time of surgery, resulting
in incomplete staging, particularly failure to obtain peritoneal cytol-
ogy. A study from the Centre Leon Berard and Institut Curie in
France13 examined the impact of incomplete staging on risk of relapse
in 38 patients (age 0.4 to 27.9 years) with stage I MOGCT. Retrospec-
tive analysis revealed incomplete staging in 56%. These patients were
classified as having stage Ix disease. This study included girls with
evidence of tumor rupture or positive peritoneal fluid cytology (Ic
according to International Federation of Gynecology and Obstetrics
staging [FIGO staging]). These patients would not have been classified
as having stage I disease by COG criteria; they would have be classified
as having stage II and III disease, respectively, and treated with chem-
otherapy at the time of diagnosis. In the French study, relapses oc-
curred only in patients with stage Ic or Ix disease (stage Ia, zero of eight;
Ic, three of three; Ix, five of 13 patients). The clustering of events in
these groups is notable and reinforces the need to assess compliance
with surgical guidelines before assignment of tumor stage and treat-
ment plan.
Despite these challenges, a surgery-only approach for pediatric
nongerminomatous MOGCT in girls age 18 years has been applied
in several centers. The SFOP (Socie´te´ Franc¸aise d’Oncologie Pe´di-
atrique) study from France14 included 12 girls with stage I ovarian
tumors similarly managed. There were six relapses. Five were received
successful salvage chemotherapy; there was one death resulting from
nonresponse. The CCSG (Children’s Cancer Study Group) study
from the United Kingdom15 included nine girls with stage I ovarian
tumors treated with surgery only. Three experienced relapse, and all
underwent successful salvage chemotherapy. The MAKEI (Maligne
Keimzelltumoren) group in Germany has also followed a surgery and
surveillance strategy for stage I nongerminomatous MOGCTs.16
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Fig 2. Event-free survival (EFS) and overall survival of pediatric and adolescent
female patients with stage I ovarian germ cell tumors.
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The application of a surgery and surveillance strategy beyond the
pediatric and adolescent age group is even more limited.14,16-19 The
heterogeneity of histologies included in these adult trials makes it
difficult to draw conclusions about the utility of the surveillance ap-
proach outside of the pediatric age group.
A difference in surgical philosophy exists between the adult and
pediatric approaches to management of ovarian malignancies; adult
gynecologic oncologists might argue that the EFS of 52% observed
among pediatric patients could be the result of the fact that extensive
sampling of lymph nodes, omentum, and peritoneal surfaces, if nor-
mal in appearance, was not mandated in the COG surgical guidelines,
leading to underdiagnosis of patients with stage I disease. The adult
surgical approach to ovarian cancer is based on experience with epi-
thelial ovarian cancer, in which aggressive local surgical control is
critical in management. However, limited information is available
regarding the yield and utility of these surgical maneuvers in adult
women with malignant germ cell tumors. This issue has been studied
in pediatric patients with MOGCTs.20 Among 131 pediatric and ado-
lescent girls with MOGCTs, pathologic analysis of sampled tissues
deemed normal by the surgeon revealed negative findings in all lymph
nodes (18 of 18), all random peritoneal biopsies (seven of seven), and
most random omental biopsies (22 of 23). In contrast, tissues judged
grossly abnormal by the surgeon intraoperatively had malignant tu-
mor in 19 of 46 lymph nodes, 18 of 29 peritoneal biopsies, and seven of
45 omental resections. Of note, five girls were confirmed to have
evidence of disease outside the ovary by positive peritoneal cytology
alone, confirming the importance of this test. The staging elements
found to be of utility in that study constituted the justification for the
revised COG surgical guidelines used in this protocol (Table 1). Al-
though it could be argued that a more thorough surgical approach
would have detected occult disease and altered the assignment of stage
I status in this study, the salvage rate with chemotherapy was equiva-
lent to OS with upfront chemotherapy, and surgical morbidity was
minimized. The value of the elements retained in the current COG
pediatric surgical guidelines is reinforced by the higher event rate in
those patients in whom the guidelines were not followed.
An open surgical approach was expected for assignment of stage I
status inthis studybecauseanintactdeliveryof thespecimentopathology
was required to confirm capsular integrity. In the pathologic review of the
prior intergroup study, we found that visual assessment of capsular integ-
rity by the surgeon was incorrect approximately 20% of the time.20 Of 51
patientsfelttohaveanintactcapsulebythesurgeon,ninewerefoundtobe
penetratedathistology,andtwowere foundtoberuptured.The largesize
of these tumors in general would have required morcellation of the spec-
imen if a laparoscopic approach had been chosen to deliver the tumor
through a small incision. Complete pathologic assessment of the capsule
would not have been possible in that situation.
Despite the increased complexity of MOGCTs in pediatric and ado-
lescent female patients, as compared with testicular germ cell tumors,
surgery followed by close surveillance resulted in excellent OS. The lower-
than-expected EFS in this population forced early closure of the trial
beforedefinitiveresultscouldbeobtainedwithnarrowCIsandprecluded
analysis of prognostic factors. Among adult men with apparently stage I
testicular cancer, certain prognostic factors, such as presence of lympho-
vascularinvasion,portendamuchhigherriskofrelapse.Thisinformation
is used productively in shared decision making between patients and
physicians about whether to proceed with chemotherapy immediately or
to undergo surveillance, with the knowledge that 50% of patients with
lymphovascular invasionwilleventuallyneedchemotherapy.Subsequent
studies should be structured with stopping rules based on OS rather than
EFS because salvage is so high with chemotherapy, which would allow for
a more robust analysis of prognostic factors among women with appar-
ently stage I ovarian germ cell tumors. However, as long as meticulous
attention is paid to surgical guidelines, and patients are carefully moni-
tored, approximately 50% to 60% of girls can be spared the potential
morbidity of chemotherapy with successful outcome.
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Table 3. Event Details
Age (years)
% YST at
Diagnosis
AFP Level (IU/L)
Relapse Confirmed by
Time to Relapse
(months)†
Survival
Diagnosis Relapse Status Survival Time (months)
Concordant-stage patients‡
2 2 9,610 153 AFP only 4 Alive 42.1
9 99 3,772 3,773 AFP only 7 Alive 79.6
13 100 497 39 Pelvic mass 5 Alive 35.8
13 60 17,285 915 Retroperitoneal mass 4 Alive 43.3
13 100 26,773 305 Pelvis and retroperitoneum 2 Alive 28.2
13 100 889 446 AFP only 4 Alive 23.4
15 99 44,115 792 Pelvis, liver, pleura 2 Alive 57.7
16 100 56,221 476 Para-aortic mass 1 Alive 29.1
16 50 494 998 Unknown site of mass 1 Dead 16.2
Discordant-stage patients‡
 1 Unknown 156 327 Retroperitoneal mass 2 Alive 22.1
10 25 13,310 146 Liver 3 Alive 42.4
11 100 2,220,000 342 AFP only 2 Alive 27.9
Abbreviations: AFP, alpha-fetoprotein; YST, yolk sac tumor.
Percentage of the tumor that was YST at diagnosis.
†Time to relapse defined as time from initial definitive surgery to first relapse.
‡Concordant or discordant means that central review of stage by study surgeons was either concordant or discordant with stage determined by institution.
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GLOSSARY TERMS
AFP (alpha-fetoprotein): A protein normally produced by
the liver of a fetus. The amount of AFP in the blood of a pregnant
woman may serve as an indicator for disorders that a growing
fetus may have, such as spina bifida, anencephaly, or Down syn-
drome. Normal values for men and nonpregnant women vary
between laboratories and range between 0 and 6.4 IU/mL or 0
and 20 ng/mL (the same as 0 to 20 g/L). In a woman who is 15 to
22 weeks pregnant, the normal values range from 19 to 75 IU/mL
or 7 to 124 ng/mL. High values in a pregnant woman may be
indicative of an inaccurate gestational age, multiple pregnancies,
a fetus with a neural tube or an abdominal wall defect, or a dead
fetus. In nonpregnant adults, a high value of AFP may indicate
cancer of the liver, testicles, or ovaries.
-HCG: The beta subunit of the human chorionic
gonadotropin.
Event-free survival: Calculated from the date of diagnosis to the
date of the first event, which is resistance, relapse, death, or second ma-
lignant neoplasm.
FIGO staging: A tumor staging system established and revised by the
International Federation of Gynecology and Obstetrics (FIGO) that
takes into account the postoperative histopathologic evaluation of the
specimen. The FIGO stage classification has prognostic value.
Overall survival: The duration between random assignment and
death.
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